Connect with us

Health

Pfizer-BioNTech vaccine shows reduced neutralization potential against SARS-CoV-2 B.1.1.7 spike variant – News-Medical.Net

Researchers in the UK have conducted a study assessing the efficacy of the Pfizer-BioNTech COVID-19 vaccine BNT162b2 against the new variant of severe acute respiratory…

Published

on

post featured image

Researchers in the UK have conducted a study assessing the efficacy of the  Pfizer-BioNTech COVID-19 vaccine BNT162b2 against the new variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).
The new B.1.1.7 variant, which has higher transmission potential than previous SARS-CoV-2 strains, recently emerged in the UK, South Africa and Brazil and has now been identified in 50 countries.
The emergence of B.1.1.7 has triggered…

Click here to view the original article.

Continue Reading
Advertisement
Advertisement

Trending